Combination therapy with inhaled glucocorticosteroids/long-acting beta-agonists in patients with bronchial asthma: choice of the best possible in real clinical practice


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The basis for the treatment of bronchial asthma (BA) includes inhaled glucocorticosteroids (IGCS), usually in combination with long-acting fc-adrenoagonists (LABA) - IGCS/LABA. As this group of drugs becomes more and more representative over time, the practitioner often faces a difficult question about choosing the “best possible". The main tool of evidence-based medicine is randomized clinical trials (RCTs), which do not always reflect real clinical practice. To this extent, the so-called pragmatic RCTs have no such disadvantage. One of them, the Salford Lung Study (SLS) is a 12-month phase III study to evaluate the efficacy and safety of the new combination drug containing modern IGCS fluticasone furoate (FF) and LABA vilanterol (VI) - 100 μg/25 μg or 200 μg/25 μg given once a day in the form of a multi-dose dry powder inhaler [23]. During the SLS, the therapeutic superiority of FF/VI over “conventional therapy" in achieving asthma control was demonstrated, and it was attributable to the clinical pharmacology features of the new combination of IGCS+LABA, including possibility of taking the drug once a day.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
MD, Professor., Head of the Department of Pulmonology

Әдебиет тізімі

  1. Global Asthma Report (December 14, 2017). Available from: http://www.globalasthmareport. org/resources/ Global_Asthma_ Report_ 2017. pdf.
  2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2019. Available from://ginasthma.org/.
  3. Hekking PP, Bel E.H. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol Pract. 2014;2:671-80. Doi: 10.1016/j. jaip.2014.09.007.
  4. Papi A., Brightling C., Pedersen S.E., Reddel H.K. Asthma. Lancet. 2018;391:783-800. doi: 10.1016/S0140-6736(17)33311-1.
  5. Howard R., Rattray M., Prosperi M., Custovic A. Distinguishing Asthma Phenotypes Using Machine Learning Approaches. Curr Allergy Asthma Rep. 2015;15-38. doi: 10.1007/s11882-015-0542-0.
  6. Skloot G.S. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med. 2016;22:3-9. Doi: 10.1097/ MCP0000000000000225.
  7. Kola I., Bell J. A call to reform the taxonomy of human disease. Nature reviews Drug discovery. 2011;10:641-42. doi: 10.1038/nrd3534.
  8. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:189-91.
  9. Heddini A, Sundh J., Ekstrom M., Janson C. Effectiveness trials: critical data to help understand how respiratory medicines really work? Eur Clin Respir J. 2919l6:1565994. doi: 10.1090/20019525.2019.1565904.
  10. Burns PB, Rohrich R.J., Chung K.C. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128:305-10. doi: 10.1097/PRS.0b013e318219c171.
  11. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2018. Available from: //ginasthma.org/
  12. Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2999;19-37. doi: 10.1186/1745-6215-10-37.
  13. Herland K., Akselsen J.P, Skj0nsberg O.H., et al. How representative are clinical study patients with asthma or COPD for a lager«real life» population of patients with obstructive lung disease? Respir Med. 2005;99:11-9.
  14. Lisspers K., Teixeira P, Blom C., et al. Are pharmacological randomized controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. NPJ Prim Care Respir Med. 2016;26:16016. doi: 10.1038/npjpcrm.2016.16.
  15. Covvey J.R., Mullen A.B., Ryan M., et al. A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014;68:1200-1208. doi: 10.1111/ijcp.12451.
  16. Rolnick S.J., Pawloski PA., Hedblom B.D., et al. Patient characteristics associated with medication adherence. Clin Med Res. 2913;11:54-65. doi: 10.3121/cmr.2013.1113.
  17. Vergresson N. Thalidomide-induced teratogenesis: history and mechanisms. Brith Defects res C Embryo Today. 2015;105:140-56. Doi: 10.1002/ bdrc.21096.
  18. lenz W. Thalidomide embryopathy in Germany, 1959-1961. Prog Clin Biol Res. 1985; 163:77-83.
  19. Ridings J.E. The thalidomide disaster, lessons from the past. Methods Mol Biol. 2013;947575-586. doi: 10.1007/978-1-62703-131-8_36.
  20. New J.P, Bakerly N.D., Leather D., Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2914;69:1152-54. Doi: 19.1136/ thoraxjnl-2014-205259.
  21. Roche N., Reddel H.K., Agusti A., et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2013;1:29-30. doi: 10.1016/S2213-2600(13)70199-1.
  22. Chalkidou K., Tunis S., Whicher D., et al. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials. 2912;9:436-46. doi: 10.1177/1740774512450097.
  23. Woodcock A., Bakerly N.D., New J.P, et al. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015;15:160. doi: 10.1186/s12890-015-0150-8.
  24. Nathan R.A., Sorkness M., Kosinski M., et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59-65.
  25. Kosinski M., Kite A., Yang M., et al. Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format. Curr Med Res Opin. 2009;25:717-27.
  26. Schatz M., Kosinski M., Yarlas A.S., et al. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2999;124:719-23. Doi: 10.1016/j. jaci.2009.06.053.
  27. Woodcock A., Vestbo J., Bakerly N.D., et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomized controlled trial. Lancet. 2017;390:2247-55. Doi: 10.1016/ S0140-6736(17)32397-8.
  28. Svedsater H., Jones R., Bosanquet N., et al. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med. 2018;141:198-206. Doi: 10.1016/j. rmed.2018.06.003.
  29. Juniper E.F., Guyatt G.H., Ferrie PJ., Griffith L.E. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147;832-38.
  30. Juniper E.F., Buist A.S., Cox F.M., et al. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115:1265-70.
  31. The EuroQol Group, EuroQol - a new facility for the measurement of health-related quality of life. Health Pol. 1990;16:199-208.
  32. Reilly M.C., Zbrozek A.S., Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-65.
  33. Travers J., Marsh S., Williams M., et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62:219-23.
  34. Price D., Chisholm A., van der Molen T., et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep. 2011;11:526-38. Doi: 10.1007/ s11882-011-0222-7.
  35. Bonora M., Wieckowsk M.R., Chinopoulos C., et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene. 2015;34(12):1608. Doi: 10.1038/ onc.2014.462.
  36. Van der Palen J., Thomas M., Chrystyn H., et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. doi: 10.1038/npjpcrm.2016.79.
  37. Kerwin E.M., Preece A., Brintziki D., et al. ELLIPTA Dry Powder Versus Metered-Dose Inhalers in an Optimized Clinical Trial Setting. J Allergy Clin Immunol Pract 2019;7:1843-49. doi: 10.1016/j.jaip.2019.02.023

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>